Clinical Trials List
2019-09-01 - 2022-09-22
Phase III
Not yet recruiting1
Recruiting4
ICD-10F31.70
Bipolar disorder, currently in remission, most recent episode unspecified
ICD-10F31.71
Bipolar disorder, in partial remission, most recent episode hypomanic
ICD-10F31.72
Bipolar disorder, in full remission, most recent episode hypomanic
ICD-10F31.9
Bipolar disorder, unspecified
ICD-9296.7
Bipolar affective disorder, unspecified
A double-blind, placebo-controlled,randomized withdrawal, multicenter clinical trial evaluating the efficacy, safety, and tolerability of cariprazine in a dose-reduction paradigm in the prevention of relapse in bipolar I disorder patients whose current episode is manic or depressive, with or without mixed features
-
Trial Applicant
PAREXEL INTERNATIONAL CO., LTD.
-
Sponsor
Allergan
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- 黃介良 Division of Ophthalmology
- Chun-JU Lin Division of Ophthalmology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- W. C. LIN Division of Ophthalmology
- Mei-Ju Chen Division of Ophthalmology
- Ya-Mei Bai Division of Ophthalmology
- 周昱百 Division of Ophthalmology
- T.P. SU Division of Ophthalmology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
25 participants
-
Global
822 participants
